Levee Medical, a Durham, NC-based clinical-stage medical device company, raised $4.3M in Seed funding.
The backers were not disclosed.
The company intends to use the funds to support its clinical and regulatory efforts, and facilitate the development and execution of a clinical strategy for its technology.
Founded by Bruce Choi, Levee Medical is committed to designing solutions that aim to reduce complications associated with surgical treatment for prostate cancer. Its product, Voro Urologic Scaffold, is a bioresorbable device designed to be placed during the robotic prostatectomy procedure for the treatment of urinary incontinence. It is designed to reduce the stress on the urinary sphincter by managing the geometry of the bladder neck and maintaining urethral length.
The company treated the first study participants in its first-in-human (FIH) study, demonstrating initial safety data for the Voro™ Urologic Scaffold. The trial will evaluate the safety and performance of the Voro Urologic Scaffold as a prophylactic treatment for post-prostatectomy stress urinary incontinence.
FinSMEs
06/09/2023